The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Keryx Biopharmaceuticals Inc

Nasdaq: KERX
Last

(U.S.) $6.22

Today's change+0.44 +7.61%
Updated June 28 4:00 PM -4GMT. Delayed by at least 15 minutes.
 

Keryx Biopharmaceuticals Inc

Nasdaq: KERX
Last

(U.S.) $6.22

Today's change+0.44 +7.61%
Updated June 28 4:00 PM -4GMT. Delayed by at least 15 minutes.

Keryx Biopharmaceuticals Inc crosses above 20-day moving average

Keryx Biopharmaceuticals Inc closed up sharply Tuesday, rallying (U.S.)$0.44 or 7.61% to (U.S.)$6.22 and crossing above its 20-day moving average. Over the last five days, shares have gained 2.81% and 23.17% year to date. Shares have underperformed the S&P 500 by 33.61% during the last year.

Key company metrics

  • Open(U.S.) $5.94
  • Previous close(U.S.) $5.78
  • High(U.S.) $6.30
  • Low(U.S.) $5.91
  • Bid / Ask(U.S.) $5.82 / (U.S.) $6.20
  • YTD % change+23.17%
  • Volume1,478,253
  • Average volume (10-day)1,432,905
  • Average volume (1-month)1,381,290
  • Average volume (3-month)1,676,068
  • 52-week range(U.S.) $2.80 to (U.S.) $10.51
  • Beta3.95
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$1.30
Updated June 28 4:00 PM -4GMT. Delayed by at least 15 minutes.
S&P TSX1.12%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q1/2016Q4/2015Q3/2015Q2/2015
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedMar 31, 201603/31/2016Dec 31, 201512/31/2015Sep 30, 201509/30/2015Jun 30, 201506/30/2015
Revenue7643
Total other revenue--------
Total revenue7643
Gross profit5412
Total cost of revenue2241
Total operating expense30313529
Selling / general / administrative21222021
Research & development88118
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total--------
Operating income-23-25-31-27
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax-41-38-31-27
Income after tax-41-38-31-27
Income tax, total0000
Net income-41-38-31-27
Total adjustments to net income--------
Net income before extra. items-41-38-31-27
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-41-38-31-27
Inc. avail. to common incl. extra. items-41-38-31-27
Diluted net income-41-38-31-27
Dilution adjustment--0----
Diluted weighted average shares106105105105
Diluted EPS excluding extraordinary itemsvalue per share-0.39-0.36-0.29-0.26
Dividends per sharevalue per share0.000.000.000.00
Diluted normalized EPSvalue per share-0.39-0.36-0.29-0.26